Catalent, Inc. (NYSE: CTLT) has issued an open letter to its customers regarding the pending acquisition by Novo Holdings. In the letter, Catalent’s President and CEO, Alessandro Maselli, addresses reported inaccuracies and reaffirms the company's commitment to continue serving customers and patients as a leading global, independent, full-service CDMO post-close.
Mr. Maselli highlighted that following the acquisition, Catalent will remain committed to providing the latest technology and capabilities, deep experience, scalable capacity, proven regulatory expertise, and a commitment to excellence. He also emphasized that the company's network of nearly 50 global sites will continue to offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies.
Furthermore, Mr. Maselli announced that he will continue to lead Catalent as President and CEO following the transaction close. He expressed excitement about partnering with all employees and Novo Holdings in the next chapter of Catalent.
Since the announcement of the pending acquisition, Catalent has experienced strong levels of new business wins across its offerings, indicating confidence and loyalty from its customers. Mr. Maselli assured that despite the acquisition, Catalent's commitments to its customers will not change, and their products will remain the company's focus, with a continued commitment to protecting proprietary information.
Catalent's acquisition by Novo Holdings is expected to close towards the end of the calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. The transaction is not subject to any financing contingency.
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients worldwide. In its 2024 fiscal year, the company generated approximately $4.4 billion in revenue and has a workforce of approximately 17,000, including more than 3,000 scientists and technicians. Catalent's flexible manufacturing platforms at over 50 global sites supply nearly 70 billion doses of nearly 8,000 products annually. The market has reacted to these announcements by moving the company's shares -0.1% to a price of $60.22. For more information, read the company's full 8-K submission here.